Researchers reveal mechanisms of how CDK12 alterations drive prostate cancer development

When researchers at the University of Michigan Rogel Cancer Center first identified a new subtype of aggressive prostate cancer, they knew they needed to understand how this genetic alteration was driving cancer and how to target it with treatment.

Tilray TLRY Stock Analysis and why TLRY stock is plummeting – what’s next for TLRY stock

May 31, 2023

Nektar updates PhIb atopic dermatitis data amid Lilly suit; Cure, Fracetat join forces on AAV platform

Nektar Therapeutics has unveiled updated results from a Phase Ib trial of its atopic dermatitis (AD) candidate, rezpegaldesleukin, in the midst of a case against

September 16, 2023

With Biden’s departure in sight, advocates seek to preserve gains of Cancer Moonshot

In President Biden’s address to the nation after dropping out of the election race, he said he would “keep fighting for my Cancer Moonshot.” He

August 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.